Recombinant Canine TrkA Protein (His Tag)
Beta LifeScience
SKU/CAT #: BLPSN-4652
Recombinant Canine TrkA Protein (His Tag)
Beta LifeScience
SKU/CAT #: BLPSN-4652
Catalog No.: BLPSN-4652
Product Overview
| Tag | His |
| Host Species | Canine |
| Accession | XP_851619.3 |
| Background | TRKA is a member of the neurotrophic tyrosine kinase receptor (NTKR) family. It is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. Isoform TrkA-III promotes angiogenesis and has oncogenic activity when overexpressed. Isoform TrkA-I is found in most non-neuronal tissues. Isoform TrkA-II is primarily expressed in neuronal cells. TrkA-III is specifically expressed by pluripotent neural stem and neural crest progenitors. The presence of NTRK1 leads to cell differentiation and may play a role in specifying sensory neuron subtypes. Mutations in TRKA gene have been associated with congenital insensitivity to pain, anhidrosis, self-mutilating behavior, mental retardation and cancer. It was originally identified as an oncogene as it is commonly mutated in cancers, particularly colon and thyroid carcinomas. TRKA is required for high-affinity binding to nerve growth factor (NGF), neurotrophin-3 and neurotrophin-4/5 but not brain-derived neurotrophic factor (BDNF). Known substrates for the Trk receptors are SHC1, PI 3-kinase, and PLC-gamma-1. NTRK1 has a crucial role in the development and function of the nociceptive reception system as well as establishment of thermal regulation via sweating. It also activates ERK1 by either SHC1- or PLC-gamma-1-dependent signaling pathway. Defects in NTRK1 are a cause of congenital insensitivity to pain with anhidrosis and thyroid papillary carcinoma.Immune CheckpointImmunotherapyCancer ImmunotherapyTargeted Therapy |
| Description | A DNA sequence encoding the canine NTRK1 (XP_851619.3) (Pro285-Lys410) was expressed with a N-terminal His tag. |
| Source | HEK293 |
| Predicted N Terminal | His |
| AA Sequence | Pro285-Lys410 |
| Molecular Weight | The recombinant canine NTRK1 comprises 146 a.a. and has a predicted molecular mass of 16.2 kDa. The apparent molecular mass of the protein is approximately 27-33 kDa in SDS-PAGE under reducing conditions due to glycosylation. |
| Purity | >95% as determined by SDS-PAGE |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
| Bioactivity | Measured by its ability to inhibit NGF-induced proliferation of TF-1 human erythroleukemic cells.The ED50 for this effect is typically 3-24 µg/mL in the presence of 10 ng/mL of recombinant human NGF. |
| Formulation | Lyophilized from sterile PBS, pH 7.4.. |
| Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
| Usage | For Research Use Only |
| Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
